Testosterone Replacement Therapy in Prostate Cancer Survivors Treated With Radiation With and Without Androgen Deprivation Therapy: A Retrospective Study and Narrative Review
Authors' conclusion
Our cohort study and narrative review found a low incidence of biochemical recurrence in prostate cancer survivors treated with radiation therapy with or without ADT. TRT was associated with correction of anemia and improvements in fatigue, energy, and sexual symptoms. These findings provide the ethical and scientific rationale for a randomized controlled trial to evaluate the safety and efficacy of TRT in this population.
Study context
- Population
- Hypogonadal men with pathology-confirmed localized prostate cancer treated with radiation with or without androgen deprivation therapy (ADT); median age at testosterone replacement therapy (TRT) initiation 75 (IQR 69.0–77.0) years
- Participants
- 33 men
- Exposure
- TRT after radiotherapy with or without ADT
- TRTn = 33
- Outcome
- Testosterone
Main finding
As reported in the abstract
Median testosterone before TRT, ng/dL (IQR 16.0-140.0)
66.0
Median testosterone on TRT, ng/dL (IQR 152.5-569.0); P < .001
299.3
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Anemia correction | TRT 42.9% |
- Anemia correction: among 21 patients with anemia
PSA
- PSA before TRT, ng/mL (IQR 0.02-0.17)
- 0.04
- PSA on TRT, ng/mL (IQR 0.04-0.44); P = .018
- 0.17
Symptoms
- TRT associated with improvements in fatigue, mood and sexual symptoms
Biochemical recurrence in published case-reports (narrative review) · mean 42.6 months of follow-up
- Weighted mean biochemical recurrence rate
- 3.3%
Safety
| Outcome | Values |
|---|---|
| Metastatic disease · 3 years after starting TRT | TRT 3% |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →